导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.05% | 1296/4773 |
| 近一周 | -1.06% | 1599/5465 |
| 近一月 | -1.27% | 1089/5421 |
| 近一季 | -4.31% | 1789/5231 |
| 近半年 | 3.26% | 948/4920 |
| 近一年 | 9.18% | 1232/4394 |
| 近两年 | 58.07% | 1289/2954 |
| 近三年 | 47.93% | 602/2253 |
| 成立以来 | 81.23% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.31% 2755/4961 |
14.86% 1748/5312 |
- - |
- - |
| 2025 | 23.03% 1914/4813 |
-0.06% 2041/3635 |
4.25% 814/4076 |
16.17% 2705/4524 |
1.64% 1288/4813 |
| 2024 | 19.09% 556/3463 |
3.87% 502/2808 |
0.81% 540/3014 |
14.55% 1953/3129 |
-0.72% 1505/3463 |
| 2023 | -4.27% 672/2656 |
4.38% 969/2280 |
-2.66% 627/2385 |
-1.49% 530/2515 |
-4.35% 973/2655 |
| 2022 | -20.86% 997/2207 |
-13.49% 767/1919 |
7.30% 495/2016 |
-12.10% 645/2113 |
-3.00% 1827/2208 |
| 2021 | -1.97% 831/1822 |
-3.30% 796/1255 |
6.46% 748/1330 |
-5.00% 762/1466 |
0.23% 1156/1822 |
| 2020 | 42.53% 264/1250 |
-6.91% 513/1028 |
17.48% 372/1067 |
15.37% 218/1164 |
12.96% 406/1184 |
| 2019 | - - |
- - |
- - |
2.04% 330/850 |
8.88% 275/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 博道沪深300指数增强A VS. 长安沪深300非周期A(740101) |